NOTICE -- Login operations are currently offline due to an unscheduled disruption. We are waiting for LDAP services to be re-instated. We apologize for the inconvenience - June 24, 2021


My research focuses on a number of efforts key to my goal in advancing therapy of melanoma.  These have focused on several areas.

First, studies of the mechanisms of resistance to MAPkinase inhibition (the foremost approach to treat patients with BRAF V600 mutant melanoma to develop better therapies.

Second developing targeted therapeutics for BRAF WT melanoma (NRAS mutant and others with so far undefined mutations to target therapy). Part of this effort has been to identify a significant number of patients whose melanoma has atypical (non-V600) BRAF mutations or a fusion (joining) of  BRAF gene to another gene which allows activation of the BRAF gene by eliminating a portion of the gene that regulates its enzyme activity. In addition to these efforts which have both led to clinical trials, I am leading a multi-institutional effort to understand the genetic and molecular underpinnings of a rare melanoma that originates from both the palms of hand and soles of the feet (acral melanoma). These have a higher percentage of melanomas without BRAF or NRAS mutations (>65%). Finally working with a soon-to-be junior faculty we have begun to look at the relationship between the genetic alterations in the tumor and the response to immunotherapy. Immunotherapy has entered center stage in therapy of  melanoma, lung cancer, and  renal cell cancer with a large number of durable remissions. However, we have no way to select patients for the new immune agents and we believe cancer genetics can assist in that essential effort.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK (2014) JAMA 311(23): 2397-405
    › Primary publication · 24938562 (PubMed) · PMC4249701 (PubMed Central)
  2. Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Johnson DB, Smalley KS, Sosman JA (2014) Clin Cancer Res 20(16): 4186-92
    › Primary publication · 24895460 (PubMed) · PMC4134689 (PubMed Central)
  3. BRAFV600E-mutant melanoma presenting with cardiac involvement. Johnson DB, Sosman JA (2014) J Natl Compr Canc Netw 12(5): 611-5
    › Primary publication · 24812130 (PubMed) · PMC4182311 (PubMed Central)
  4. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W (2014) Oncologist 19(6): 616-22
    › Primary publication · 24797823 (PubMed) · PMC4041676 (PubMed Central)
  5. Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, Wallace DE, Dickson MA, Kudchadkar RR, Sosman JA (2015) J Clin Oncol 33(33): e122-4
    › Primary publication · 24778401 (PubMed) · PMC4979104 (PubMed Central)
  6. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z (2014) Mol Cancer Ther 13(7): 1918-28
    › Primary publication · 24755198 (PubMed) · PMC4090262 (PubMed Central)
  7. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W (2014) Clin Cancer Res 20(9): 2264-75
    › Primary publication · 24599935 (PubMed) · PMC4008689 (PubMed Central)
  8. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) J Clin Oncol 32(10): 1020-30
    › Primary publication · 24590637 (PubMed) · PMC4811023 (PubMed Central)
  9. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A (2014) Lancet Oncol 15(3): 323-32
    › Primary publication · 24508103 (PubMed) · PMC4382632 (PubMed Central)
  10. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA (2013) Cancer Immunol Res 1(6): 373-7
    › Primary publication · 24490176 (PubMed) · PMC3905602 (PubMed Central)
  11. New options and new questions: how to select and sequence therapies for patients with metastatic melanoma. Flaherty KT, Sosman JA, Atkins MB (2012) Am Soc Clin Oncol Educ Book : 524-30
    › Primary publication · 24451790 (PubMed)
  12. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W (2013) Clin Cancer Res 19(24): 6696-702
    › Primary publication · 24345920 (PubMed) · PMC3880773 (PubMed Central)
  13. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS (2014) Cancer Discov 4(1): 80-93
    › Primary publication · 24265155 (PubMed) · PMC3936420 (PubMed Central)
  14. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB (2013) Nat Rev Clin Oncol 10(10): 588-98
    › Primary publication · 23982524 (PubMed)
  15. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD (2013) J Clin Oncol 31(4): 482-9
    › Primary publication · 23248257 (PubMed) · PMC4878037 (PubMed Central)
  16. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A (2013) EMBO Mol Med 5(1): 149-66
    › Primary publication · 23180582 (PubMed) · PMC3569660 (PubMed Central)
  17. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J (2012) N Engl J Med 367(18): 1694-703
    › Primary publication · 23020132 (PubMed) · PMC3549295 (PubMed Central)
  18. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J (2012) Nature 487(7408): 505-9
    › Primary publication · 22763448 (PubMed) · PMC3724525 (PubMed Central)
  19. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ (2012) Cancer 118(24): 6055-62
    › Primary publication · 22674198 (PubMed) · PMC3934426 (PubMed Central)
  20. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) N Engl J Med 366(26): 2443-54
    › Primary publication · 22658127 (PubMed) · PMC3544539 (PubMed Central)
  21. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS (2012) Cancer Discov 2(5): 414-24
    › Primary publication · 22588879 (PubMed) · PMC3594852 (PubMed Central)
  22. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W (2012) PLoS One 7(4): e35309
    › Primary publication · 22536370 (PubMed) · PMC3335021 (PubMed Central)
  23. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, Sosman JA, Lee RJ, Nolop K, Flaherty KT, Callahan J, Hicks RJ (2012) J Clin Oncol 30(14): 1628-34
    › Primary publication · 22454415 (PubMed) · PMC5950495 (PubMed Central)
  24. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS (2012) Nat Commun : 724
    › Primary publication · 22395615 (PubMed) · PMC3530385 (PubMed Central)
  25. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R (2012) N Engl J Med 366(3): 207-15
    › Primary publication · 22256804 (PubMed) · PMC3724537 (PubMed Central)
  26. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL, Othus M, Sosman JA, Kirkwood JM, Sondak VK (2012) Clin Cancer Res 18(4): 1129-37
    › Primary publication · 22228638 (PubMed) · PMC3481165 (PubMed Central)
  27. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ (2012) J Clin Oncol 30(1): 34-41
    › Primary publication · 22124101 (PubMed) · PMC4669379 (PubMed Central)
  28. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB (2011) Nature 480(7377): 387-90
    › Primary publication · 22113612 (PubMed) · PMC3266695 (PubMed Central)
  29. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R (2012) Clin Cancer Res 18(2): 555-67
    › Primary publication · 22048237 (PubMed) · PMC3549298 (PubMed Central)
  30. A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors. Wang-Gillam A, Tew WP, Rothenberg ML, Dupont J, Cooper W, Sternas L, Buzenet G, Sosman JA, Spriggs DR, Lockhart AC (2012) Invest New Drugs 30(5): 1958-61
    › Primary publication · 22002018 (PubMed) · PMC3432791 (PubMed Central)
  31. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group (2011) N Engl J Med 364(26): 2507-16
    › Primary publication · 21639808 (PubMed) · PMC3549296 (PubMed Central)
  32. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M (2010) Cancer Cell 18(6): 683-95
    › Primary publication · 21156289 (PubMed) · PMC3026446 (PubMed Central)
  33. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (2010) Nature 468(7326): 973-7
    › Primary publication · 21107323 (PubMed) · PMC3143360 (PubMed Central)
  34. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K (2010) Nature 467(7315): 596-9
    › Primary publication · 20823850 (PubMed) · PMC2948082 (PubMed Central)
  35. Inhibition of mutated, activated BRAF in metastatic melanoma. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) N Engl J Med 363(9): 809-19
    › Primary publication · 20818844 (PubMed) · PMC3724529 (PubMed Central)
  36. Improved survival with ipilimumab in patients with metastatic melanoma. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) N Engl J Med 363(8): 711-23
    › Primary publication · 20525992 (PubMed) · PMC3549297 (PubMed Central)
  37. Aberrant DNA methylation in malignant melanoma. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally J, Verma A (2010) Melanoma Res 20(4): 253-65
    › Primary publication · 20418788 (PubMed) · PMC3026062 (PubMed Central)
  38. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Buzoianu M, Hammershaimb L, Kirkwood JM, Etaracizumab Melanoma Study Group (2010) Cancer 116(6): 1526-34
    › Primary publication · 20108344 (PubMed)
  39. Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E, Bastian B, Landi MT, Landi TM, Sosman J (2010) Pigment Cell Melanoma Res 23(1): 14-26
    › Primary publication · 20025711 (PubMed)
  40. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK (2010) Cancer 116(2): 424-31
    › Primary publication · 19918923 (PubMed) · PMC2811758 (PubMed Central)
  41. Dacarbazine induced acute myeloid leukemia in melanoma. Collins CM, Morgan DS, Mosse C, Sosman J (2009) Melanoma Res 19(5): 337-40
    › Primary publication · 19741425 (PubMed)
  42. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L (2009) Cancer 115(10 Suppl): 2247-51
    › Primary publication · 19402064 (PubMed) · PMC2892290 (PubMed Central)
  43. Combination targeted therapy in advanced renal cell carcinoma. Sosman J, Puzanov I (2009) Cancer 115(10 Suppl): 2368-75
    › Primary publication · 19402058 (PubMed)
  44. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. Cho DC, Puzanov I, Regan MM, Schwarzberg T, Seery V, Lee MY, Liu V, Bhatt R, Koon H, Mier JW, Sosman JA, Atkins MB, McDermott DF (2009) J Immunother 32(2): 181-5
    › Primary publication · 19238017 (PubMed)
  45. Phase I/II trial of tremelimumab in patients with metastatic melanoma. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A (2009) J Clin Oncol 27(7): 1075-81
    › Primary publication · 19139427 (PubMed)
  46. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM, Eastern Cooperative Oncology Group (2008) J Clin Oncol 26(35): 5748-54
    › Primary publication · 19001327 (PubMed) · PMC2645104 (PubMed Central)
  47. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, Lawson D, Dutcher JP, Weiss G, Curti B, Margolin KA (2008) Cancer 113(8): 2139-45
    › Primary publication · 18792064 (PubMed)
  48. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ (2008) J Clin Oncol 26(22): 3743-8
    › Primary publication · 18669461 (PubMed)
  49. Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Moore SR, Persons DL, Sosman JA, Bobadilla D, Bedell V, Smith DD, Wolman SR, Tuthill RJ, Moon J, Sondak VK, Slovak ML (2008) Clin Cancer Res 14(10): 2927-35
    › Primary publication · 18483359 (PubMed)
  50. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E (2008) J Clin Oncol 26(13): 2178-85
    › Primary publication · 18445842 (PubMed)
  51. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Hainsworth JD, Spigel DR, Sosman JA, Burris HA, Farley C, Cucullu H, Yost K, Hart LL, Sylvester L, Waterhouse DM, Greco FA (2007) Clin Genitourin Cancer 5(7): 427-32
    › Primary publication · 18272024 (PubMed)
  52. Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study. Clark JI, Mehrabi J, Sosman JA, Logan TF, Margolin KA, Dutcher JP, Urba WJ, Ernstoff MS, McDermott DF, Lau AM, Atkins MB (2007) J Immunother 30(8): 839-46
    › Primary publication · 18049336 (PubMed)
  53. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Fricke I, Mirza N, Dupont J, Lockhart C, Jackson A, Lee JH, Sosman JA, Gabrilovich DI (2007) Clin Cancer Res 13(16): 4840-8
    › Primary publication · 17699863 (PubMed)
  54. Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW, Clark JI, Baar J, Sosman J, Weber J, Lathia C, Brunetti J, Cihon F, Schwartz B (2007) Clin Cancer Res 13(11): 3312-9
    › Primary publication · 17545537 (PubMed)
  55. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial (2007) N Engl J Med 356(22): 2271-81
    › Primary publication · 17538086 (PubMed)
  56. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L (2007) Clin Cancer Res 13(2 Pt 2): 667s-670s
    › Primary publication · 17255291 (PubMed)
  57. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML (2006) Clin Cancer Res 12(9): 2834-40
    › Primary publication · 16675578 (PubMed)
  58. Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L (2006) Clin Cancer Res 12(7 Pt 2): 2291s-2296s
    › Primary publication · 16609047 (PubMed)